Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

NCT03430791 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Study Investigator/Sponsor decided to end enrollment earlier.

Conditions

Recurrent Glioblastoma

Interventions

DRUG: Nivolumab 240 mg IV
DRUG: Nivolumab 3 mg/kg
DRUG: Ipilimumab 1 mg/kg
DEVICE: NovoTTF200A (Optune)

Sponsor

Baptist Health South Florida

Collaborators

[object Object]
[object Object]